Document is current
Any future updates will be listed below
-
Authors
Djuari, M. A. https://orcid.org/0009-0004-4493-1031
Londenberg, A. https://orcid.org/0009-0007-8268-8601
Bassan, A. https://orcid.org/0000-0003-1748-3144
Cross, K. https://orcid.org/0000-0002-2462-0533
Elenschneider, L. https://orcid.org/0000-0003-4714-2156
Escher, S. E. https://orcid.org/0000-0001-9616-527X
Fahrer, J. https://orcid.org/0000-0001-5225-2718
Fangmann, J. https://orcid.org/0000-0002-0108-1346
Felske, C. https://orcid.org/0009-0008-8806-7387
Frötschl, R. https://orcid.org/0000-0001-8721-7509
Haas, B. https://orcid.org/0000-0002-1213-3527
Johnson, G. E. https://orcid.org/0000-0001-5643-9942
Vogel, M. https://orcid.org/0000-0003-4814-3900
Whomsley, R. https://orcid.org/0000-0001-6108-9908
Ziemann, C. https://orcid.org/0000-0002-3238-5385
-
Funding
Funding for this research was provided by:
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM
- License Information
-
More Information
Article History
Received: 26 March 2026
Accepted: 18 May 2026
First Online: 2 June 2026
Declarations
Conflict of interest: This document expresses the opinion of the authors of the paper and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties. A.B. & G.E.J. are consultants who evaluate the risks posed by pharmaceutical impurities. Their clients did not influence the content of this manuscript. Other authors declare that they have no conflict of interest.
